License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($)												1 Months Ended							12 Months Ended
	Dec. 05, 2019	Dec. 04, 2019	Aug. 07, 2019	Sep. 05, 2018	Sep. 05, 2018	Dec. 04, 2017	Aug. 31, 2015	Aug. 29, 2015	Aug. 10, 2015	Dec. 05, 2013	Oct. 05, 2012	Dec. 06, 2018	Jan. 17, 2017	Aug. 31, 2015	Aug. 29, 2015	Dec. 19, 2012	Dec. 19, 2012	Nov. 28, 2012	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2015
License, Collaborative and Employment Agreements and Commitments [Line Items]
Line of Credit Facility, Periodic Payment, Interest																			$ 381,150
Salary and Wage, Officer, Excluding Cost of Good and Service Sold																					$ 385,000
Payments for Other Fees						$ 4,500,000
Payments to Acquire in Process Research and Development				$ 441,000
Exchange percentage of unregistered common stock																			50.00%
Proceeds from (Repurchase of) Equity					$ 3,000,000														$ 3,000,000
Options To Be Received Common Stock Shares																			2,000,000
Fair Value Of Shares Issued				$ 285,000
Operating Lease, Cost																			$ 201,000	$ 201,000
Operating Lease, Payments																			300,000
Non Cash Addition of Right of Use Assets																			$ 537,000
Operating Lease, Weighted Average Discount Rate, Percent																			9.90%
Licensing Agreements [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Annual payments due under license agreement																$ 50,000
Final payment due under license agreement																25,000
Payments for Other Fees										$ 150,000
Stock Issued During Period, Shares, New Issues										9,569
Patents [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Payments for Other Fees										$ 220,000
Riley Employment Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold						$ 200,000
Deferred Compensation Arrangement with Individual, Compensation Expense													$ 550,000						$ 5,397
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage													75.00%
Shallcross Employment Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Cash Payment for License Agreement																			8,000
Deferred Compensation Arrangement with Individual, Compensation Expense		$ 565,000										$ 550,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage												75.00%
Jeffrey Riley [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage																					75.00%
Steven A. Shallcross [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Shares Issued, Price Per Share		$ 0.418
Cost of Living Adjustments Percentage	3.00%
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 565,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage		75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		450,000
Intrexon [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Stock Issued During Period, Shares, Acquisitions											101,492
Shares Issued, Price Per Share											$ 0.001
Milestone Payment upon First Dosing									$ 2,000,000										$ 2,000,000
Prev Abr Llc [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Additional Cash Payment for License Agreement																		$ 235,000
Unregistered Shares Issued to License Agreement																		17,858
Additional Consideration Payable																		50% in cash and 50% in our stock
Options To Be Received Common Stock Shares																					18,724
Phase I Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment																	$ 50,000
Phase III Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment																	100,000
NDA Submission In US [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment																	250,000
European Medicines Agency Approval [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment																	100,000
Regulatory Approval In Asian Country [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment																	100,000
PKU ECC [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Shares, Issued									26,786
Stock Issued									$ 3,000,000
Stock Purchase Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Conversion of Stock, Shares Converted															38,572
Conversion of Stock, Shares Issued							38,572	38,572						38,572
Clinical Trial Agreement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Estimated Research Costs			$ 3,200,000
First Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee																303,287	303,287
Second Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee																316,438	316,438
Third Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee																$ 328,758	$ 328,758